Contents

1 Adverse Reactions to Drugs and Drug Allergy: Scope of This Book 1
1.1 Adverse Drug Reactions 1
1.1.1 Definition 1
1.1.2 Terminology: Classification of Adverse Drug Reactions and the terms Hypersensitivity, and Allergy 2
1.1.3 Usage of the Term "Allergy" 5
1.2 Drug Allergy 6
1.2.1 The Early Years 6
1.2.2 Drugs, Haptens, and Prior Exposure 6
1.2.3 Drug Allergies, Hypersensitivities, and Sensitivities (Intolerances) 7
1.2.4 Risk Factors for Drug Allergy 8
1.3 The Promise of Pharmacogenomics for understanding and managing Adverse Drug Reactions Including Drug Allergies 9
1.4 Improvements In Drug Delivery and the Allergenicity of Drugs 11
1.5 Scope of This Book 11
1.5.1 The Place of Drug Allergy in Immunology 11
1.5.2 The Need for a Single Text Book on Drug Allergy 12
Summary 12
Further Reading 13

2 Classification and Descriptions of Allergic Reactions to Drugs 15
2.1 Hypersensitivity: The Early Years—From Koch to Gell and Coombs 16
2.2 Classification of Hypersensitivity Reactions 16
2.2.1 Type I Hypersensitivity 16
2.2.2 Type II Hypersensitivity 23
2.2.3 Type III Hypersensitivity 23
2.2.4 Delayed-Type (Type IV) Hypersensitivity 24
Summary 34
Further Reading 35

3 Mechanisms of Hypersensitivity 37
3.1 Allergic Sensitization to Drugs and the Dogma of Previous Exposure 38
3.1.1 Immunogenicity of Free and Conjugated Drugs 38
3.1.2 Mediator Release by Free and Conjugated Drugs in Immediate Allergic Reactions 40
3.1.3 Immunological Recognition of Free, Unconjugated Drug Molecules 41
3.2 IgE Antibodies and IgE-Mediated Drug Hypersensitivities 42
3.2.1 Initiating Events in the Production of IgE Antibody 42
3.2.2 Allergic Release of Mediators of Hypersensitivity from Mast Cells 43
3.2.3 Amplification of IgE Antibody Production by Cellular Interaction 45
3.2.4 Low-Affinity IgE Receptor FcεRII (CD23) 45
3.2.5 Important Mediators of the Type I Immediate Allergic Response 46
3.2.6 Anaphylaxis 58
3.2.7 Other Mechanisms of Anaphylaxis: IgG, PAF, and Nitric Oxide 61
3.2.8 Drug-Induced Urticaria and Angioedema 62
3.3 The Allergen-Induced Late Phase Reaction 68
3.3.1 Early Studies: Implication of IgE Antibodies 69
3.3.2 Cellular Responses in the Late Phase Reaction and Comparison with the Delayed-Type Hypersensitivity Response 69
3.4 Drug-Induced Hypersensitivity and Immune Receptors 70
3.4.1 Background 70
3.4.2 Recognition and the Immune Response to Free, Unconjugated Drug 71
3.4.3 Abacavir and the MHC-Presented Altered Peptide Model of Drug Hypersensitivity 72
3.4.4 Carbamazepine and Other HLA-Drug Hypersensitivity Associations 73
3.4.5 The Question of Direct Drug Activation of T Cells Without Involvement of a Specific Peptide 74
3.5 Desensitization of Drug-Allergic Patients 75
3.6 Delayed-Type (Type IV) Hypersensitivity Drug Reactions 76
3.6.1 The Cellular Basis of Type IV Hypersensitivity Cutaneous Drug Reactions 76
3.6.2 T Helper Cell Responses and Th17 78
3.6.3 Delayed Cutaneous Adverse Drug Reactions 79
3.7 Type II Hypersensitivity Drug Reactions 84
3.8 Type III Hypersensitivity Drug Reactions 86
Summary 87
Further Reading 90

4 Diagnosis of Allergic Reactions to Drugs 91
4.1 Case History 92
4.2 Skin Testing 93
4.2.1 General Aspects of Skin Testing for Drug Hypersensitivity 93
4.2.2 Skin Prick Test Method 94
4.2.3 Intradermal Testing 95
4.2.4 Patch Tests 97
4.3 Serum Immunoglobulin E Antibody Tests 100
4.3.1 In Vitro Detection of Drug-Reactive IgE Antibodies 101
4.3.2 Tests for the Clinic and Research 103
4.3.3 Quantitation, Interpretation and Reporting of Results 104
4.4 Drug Challenge (Provocation) Testing 105
4.5 Detection and Measurement of Released Mediators/Markers of Hypersensitivity 107
4.5.1 Tryptase 107
4.5.2 Histamine 109
4.5.3 Cysteinyl Leukotrienes 111
4.6 Basophil Activation Test 113
4.6.1 Basophils and Background to the Basophil Activation Test (BAT) 113
4.6.2 Basophil Activation Markers 114
4.6.3 Some Technical Aspects 115
4.6.4 Controls 116
4.6.5 Evaluation of Results 116
4.6.6 Application to Drug Allergies 117
4.6.7 Analysis by Flow Cytometry of Intracellular Histamine and Its Release by Activated Basophils at the Single Cell Level 117
4.6.8 Future Research and Conclusions 118
4.7 Tests for Delayed Type Drug Hypersensitivity Reactions 118
4.7.1 Lymphocyte Transformation Test 120
4.7.2 The Local Lymph Node Assay 121
4.7.3 Toward Nonproliferation-Based In Vitro Assays: Cell Surface Activation Markers, Cytokines, Chemokines, and Skin-Homing Receptors 121
4.8 And Finally: Is the Patient Allergic to the Drug? 124
Summary 125
Further Reading 127

5 β-Lactam Antibiotics 129
5.1 Penicillins 131
5.1.1 Incidence of Penicillin Hypersensitivity and Clinical Aspects 131
5.1.2 Penicillin Antigens and Allergenic Determinants 132
5.1.3 Heterogeneity of IgE Antibody Responses to Penicillins and the Spectrum of Penicillin Allergenic Determinants 141

5.1.4 Risk Factors for Immediate (Type I) Reactions to Penicillins 147
5.1.5 Skin Testing Today for Immediate Hypersensitivity to Penicillin 148
5.1.6 In Vitro Tests for Immediate Hypersensitivity to Penicillins 151
5.1.7 Challenge (Provocation) Testing for Penicillin Hypersensitivity 153
5.1.8 Penicillin Desensitization 154
5.1.9 Delayed-Type Hypersensitivity Reactions to Penicillins 156
5.1.10 The Genetic Basis of Penicillin-Induced Liver Injury 159
5.2 Cephalosporins 159
5.2.1 Incidence of Cephalosporin Hypersensitivity and Clinical Aspects 160
5.2.2 Clinical Aspects of Cross-Reactivity of Cephalosporins and Penicillins 160
5.2.3 Structures and Classification of Cephalosporin Drugs 161
5.2.4 Cephalosporin Antigens and Allergenic Determinants 161
5.2.5 Skin Testing with Cephalosporins 173
5.2.6 Delayed Reactions to Cephalosporins 174
5.3 Monobactams 175
5.4 Carbapenems 176
5.5 Clavams 177
Summary 178
Further Reading 180

6 Other Antimicrobial Drugs 183
6.1 Antibiotics 184
6.1.1 Macrolides 184
6.1.2 Tetracyclines 186
6.1.3 Rifamycins 187
6.1.4 Vancomycin and Teicoplanin 188
6.1.5 Antibiotics Used Topically with Emphasis on Neomycin and Bacitracin 193
6.1.6 Ribostamycin 197
6.1.7 Chloramphenicol 198
6.1.8 Clindamycin 198
6.1.9 Pristinamycin 200
6.1.10 Fosfomycin 200
6.2 Antimicrobials Other than Antibiotics 200
6.2.1 Sulfonamides 200
6.2.2 Trimethoprim 213
6.2.3 Quinolones 218
6.2.4 Chlorhexidine 225
6.2.5 Povidone–Iodine 230
Summary 231
Further Reading 232

7 Drugs and Other Agents Used in Anesthesia and Surgery 235
7.1 Drug-Induced Reactions During Anesthesia 235
7.2 Incidences of Drug- and Other Agent-Induced Anaphylaxis During Anesthesia 237
7.3 Clinical Features of Anaphylactic and Anaphylactoid Reactions During Anesthesia 238
7.4 Anaphylaxis to Neuromuscular Blocking Drugs 239
7.4.1 Some Epidemiological Background 239
7.4.2 Mechanisms Underlying Anaphylaxis to Neuromuscular Blocking Drugs 240
7.4.3 Diagnosis of Anaphylaxis to Neuromuscular Blocking Drugs 246
7.4.4 Cross-Reactions Between Neuromuscular Blocking Drugs 256
7.4.5 The NMBD–IgE Conundrum: The Origin of IgE Antibodies to Neuromuscular Blocking Drugs 263
7.4.6 Sugammadex and Anaphylaxis to Rocuronium 267
7.4.7 Antigenic Similarity Between α-Bungarotoxin and Neuromuscular Blocking Drugs 272
7.5 Anaphylaxis to Hypnotic Drugs Used in Anesthesia 273
7.5.1 Thiopentone 273
7.5.2 Propofol 276
7.6 Anaphylaxis to Colloids 278
7.6.1 Hydroxyethyl Starch 278
7.6.2 Gelatin 279
7.6.3 Dextrans 279
7.7 Local Anesthetics 281
7.7.1 Chemistry 281
7.7.2 Adverse Reactions to Local Anesthetics 281
7.7.3 Diagnosis of Reactions to Local Anesthetics 284
7.8 Polypeptides 284
7.8.1 Protamine 284
7.8.2 Aprotinin 286
7.8.3 Latex 287
7.9 Heparin 289
7.9.1 Adverse Reactions to Heparin 289
7.9.2 Diagnostic Methods 289
7.9.3 Danaparoid and Hirudins 290
7.9.4 Fondaparinux 290
7.10 Patent Blue V, Isosulfan Blue, and Methylene Blue 291
Summary 293
Further Reading 294

8 Opioid Analgesic Drugs 295
8.1 Terminology 296
8.2 Structure–Activity Relationships 296
8.3 Classification of Opioid Drugs 301
8.4 Opioids and Histamine Release 303
8.4.1 Histamine Receptors 303

8.4.2 Early Studies on Opioid Drug-Induced Release of Histamine 304
8.4.3 Summary of Morphine-Induced Hemodynamic and Cutaneous Changes in Humans 305
8.5 Allergenicity of Opioid Analgesic Drugs 308
8.5.1 Naturally Occurring and Semisynthetic Opioid Drugs 308
8.5.2 Synthetic Opioid Drugs 311
8.6 Resolving the Histamine-Releasing and Allergenic Effects in Diagnosing Reactions to Opioid Drugs 313
8.7 Why Are Opioid Analgesic Drugs So Poorly Allergenic? 315
8.8 Some Important Clinical Implications Related to the Use of Opioid Analgesic Drugs 316
Summary 317
Further Reading 317

9 Nonsteroidal Anti-Inflammatory Drugs 319
9.1 Therapeutic Applications of NSAIDs 320
9.2 Patient Usage 320
9.3 Classification of NSAIDs 321
9.3.1 Salicylates 321
9.3.2 Propionic Acid Derivatives 321
9.3.3 Aryl and Heteroaryl Acetic Acids 321
9.3.4 Anthranilates (Fenamic Acid Derivatives) 323
9.3.5 Oxicams (Enolic Acid Derivatives) 323
9.3.6 Phenylpyrazolones 323
9.3.7 Anilides 323
9.3.8 COX-2 Selective Inhibitors 323
9.4 Mechanism of Action of NSAIDs 324
9.4.1 Biosynthesis of the Prostanoids 324
9.4.2 The Cyclooxygenase Isoforms COX-1 and COX-2 324
9.4.3 Classification of NSAIDs by COX Isoenzyme Selectivity 326
9.4.4 The So-Called COX-3 Isoform 327
9.5 Sensitivities to NSAIDs 328
9.5.1 Definition and Epidemiology 329
9.5.2 Clinical Classification of Sensitivities to NSAIDs 330
9.5.3 IgE Antibodies to Aspirin 339
9.5.4 NSAID Sensitivities and BAT 340
9.5.5 Genetic Mechanisms of Aspirin-Induced Sensitivities 340
Summary 341
Further Reading 342

10 Contrast Media 343
10.1 Iodinated Contrast Media 344
10.2 Usage and Safety of Contrast Media 346
10.3 Adverse Reactions 347
10.3.1 Classification and Symptoms 347

10.3.2 Incidence of Reactions ... 349
10.3.3 Risk Factors ... 350
10.3.4 Biphasic Reactions ... 350
10.4 Mechanisms of Adverse Reactions to Iodinated Contrast Media ... 351
10.4.1 Anaphylactoid and Anaphylactic Reactions ... 352
10.4.2 Delayed Reactions ... 355
10.5 Tests for the Diagnosis and Study of Adverse Reactions to Contrast Media ... 356
10.5.1 Skin Tests ... 356
10.5.2 IgE Antibody Tests ... 357
10.5.3 Tests to Detect the Release of Mediators ... 358
10.5.4 Challenge Tests ... 359
10.6 Premedication for the Prevention of Anaphylactoid/Anaphylactic Reactions to Iodinated Contrast Media ... 360
10.7 Gadolinium-Based Contrast Agents ... 361
10.7.1 Molecular Structures of Gadolinium-Based Contrast Agents ... 361
10.7.2 Nephrogenic Systemic Fibrosis ... 361
10.7.3 Other Adverse Reactions ... 361
Summary ... 365
Further Reading ... 366

11 Biologics ... 369
11.1 Monoclonal Antibodies for Therapy ... 370
11.1.1 Nomenclature ... 370
11.1.2 Monoclonal Antibodies Approved for Therapy ... 370
11.1.3 Immune Reactions to Monoclonal Antibodies ... 371
11.2 Etanercept ... 379
11.3 Interferons ... 380
11.4 Interleukin 2 ... 380
11.5 Denileukin Diftitox and Aflibercept ... 381
11.6 Anakinra ... 381
11.7 Anti-thymocyte Globulin ... 382
11.8 Epoetins ... 382
11.9 Human Insulin ... 383
Summary ... 384
Further Reading ... 385

12 Corticosteroids ... 387
12.1 Introduction, Incidence of Allergy, and Sensitization ... 387
12.2 Corticosteroid Haptens: Metabolism and Degradation ... 388
12.3 Delayed Reactions ... 390
12.3.1 Clinical Presentation ... 390
12.3.2 Diagnosis of Corticosteroid Hypersensitivity ... 390
12.3.3 Structure–Activity Relationships of Corticosteroid Cross-Reactions ... 393
12.4 Immediate Reactions to Corticosteroids ... 394
12.4.1 Incidence, Sensitization, Clinical Presentation, and Risk Factors ... 394

12.4.2 Immediate reactions: Important/Interesting Findings and Observations Reported so Far 394
12.4.3 Identifying and Understanding Cross-Reactions: Finding a Safe Alternative Corticosteroid 396
12.4.4 Diagnostic Methods 396
Summary 397
Further Reading 397

13 Drugs Used for Chemotherapy 399
13.1 Taxanes 400
13.1.1 Premedication for Taxanes 404
13.1.2 Desensitization for Hypersensitivity Reactions to Taxanes 405
13.2 Organoplatinum Chemotherapeutic Drugs 405
13.2.1 Symptoms of Hypersensitivity to Platinum Drugs 405
13.2.2 Incidences of, and Risk Factors for, Hypersensitivity Reactions to Platinum Drugs 407
13.2.3 Mechanisms and Diagnosis of Platinum Drug-Induced Hypersensitivity Reactions 407
13.2.4 Desensitization 408
13.3 Tyrosine Kinase Inhibitors 409
13.3.1 The Philadelphia Chromosome and Tyrosine Kinases 409
13.3.2 Imatinib Mesylate 410
13.3.3 Gefitinib and Erlotinib 411
13.4 Proteasome Inhibitors 412
13.4.1 The Proteasome 412
13.4.2 Bortezomib 412
13.4.3 Second Generation Proteasome Inhibitors 415
13.5 Cytokine-release and tumor lysis syndromes 415
Summary 415
Further Reading 417

14 Proton Pump Inhibitors 419
14.1 Chemistry 419
14.2 Mechanism of Action 420
14.3 Hypersensitivity Reactions to Proton Pump Inhibitors 420
14.4 Diagnosis of Hypersensitivity to Proton Pump Inhibitors 422
14.5 Proton Pump Inhibitors, Gastroesophageal Reflux Disease, and Asthma 423
14.6 Other Safety Concerns with Proton Pump Inhibitors 423
Summary 423
Further Reading 424

Postface – Concluding Remarks 425

Index 429